Physician profile
Michael Jurgens
NPI 1649244294
$1,340.69
in general payments reported to CMS, 2019-2025
24 companies · $165 in 2025
The $165 reported for 2025 was more than what a typical Diagnostic Radiology provider received nationally (typical 2025 total: $112).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81.93 · 2021: $247 · 2022: $192 · 2023: $530 · 2024: $124 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $819.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $819.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $401.93 | 2023-2024 | Cabometyx |
| Daiichi Sankyo INC. | $106.20 | 2021-2023 | Enhertu |
| Merck Sharp & Dohme LLC | $83.84 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $77.91 | 2021-2022 | |
| Genentech USA, INC. | $74.98 | 2023-2024 | Tecentriq, Alecensa, Columvi |
| Seagen INC. | $72.87 | 2021 | |
| Pfizer INC. | $69.12 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $56.42 | 2021-2023 | Libtayo |
| Amgen INC. | $44.22 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $39.79 | 2019-2023 | Enhertu |
| Stryker Corporation | $35.05 | 2025 | Molli |
| Pharmacyclics LLC, An Abbvie Company | $26.43 | 2022 | |
| Janssen Biotech, INC. | $25.16 | 2022 | |
| Fennec Pharmaceuticals, INC. | $24.28 | 2024 | Pedmark |
| Mirati Therapeutics, INC. | $23.68 | 2024 | Krazati |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $22.10 | 2025 | |
| Hologic Sales and Service, LLC | $21.61 | 2025 | 3dimensions, I -View Contrast Enhanced Digital Mammography, Magseed |
| Novartis Pharmaceuticals Corporation | $21.51 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.88 | 2022 | |
| Sumitomo Pharma America, INC. | $20.21 | 2025 | Orgovyx |
| Bayer Healthcare Pharmaceuticals INC. | $19.65 | 2023 | |
| Abbvie INC. | $19.26 | 2019 | |
| Genzyme Corporation | $18.42 | 2021 | |
| Pharmacosmos Therapeutics INC. | $15.17 | 2025 | Monoferric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Jurgens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.